Challenges for a universal Staphylococcus aureus vaccine.
about
The Role of Staphylococcus aureus Virulence Factors in Skin Infection and Their Potential as Vaccine AntigensWill there ever be a universal Staphylococcus aureus vaccine?Where does a Staphylococcus aureus vaccine stand?Selective chemical inhibition of agr quorum sensing in Staphylococcus aureus promotes host defense with minimal impact on resistancePushing the frontiers of T-cell vaccines: accurate measurement of human T-cell responses.A model-based analysis: what potential could there be for a S. aureus vaccine in a hospital setting on top of other preventative measures?The bicomponent pore-forming leucocidins of Staphylococcus aureusDesign of live attenuated bacterial vaccines based on D-glutamate auxotrophy.Identifying functional anti-Staphylococcus aureus antibodies by sequencing antibody repertoires of patient plasmablasts.Phenol-soluble modulins--critical determinants of staphylococcal virulence.Propionibacterium-produced coproporphyrin III induces Staphylococcus aureus aggregation and biofilm formation.Applying Convergent Immunity to Innovative Vaccines Targeting Staphylococcus aureus.Humanized staphylococcal enterotoxin B (SEB)-specific monoclonal antibodies protect from SEB intoxication and Staphylococcus aureus infections alone or as adjunctive therapy with vancomycinOpsonic and protective properties of antibodies raised to conjugate vaccines targeting six Staphylococcus aureus antigens.Passive immunization with anti-glucosaminidase monoclonal antibodies protects mice from implant-associated osteomyelitis by mediating opsonophagocytosis of Staphylococcus aureus megaclusters.Mechanisms of NDV-3 vaccine efficacy in MRSA skin versus invasive infection.Recombinant ESAT-6-like proteins provoke protective immune responses against invasive Staphylococcus aureus disease in a murine model.Characterization of a mouse-adapted Staphylococcus aureus strain.Protective activity of the CnaBE3 domain conserved among Staphylococcus aureus Sdr proteins.Protein A suppresses immune responses during Staphylococcus aureus bloodstream infection in guinea pigs.Vaccine composition formulated with a novel TLR7-dependent adjuvant induces high and broad protection against Staphylococcus aureusOne Dose of Staphylococcus aureus 4C-Staph Vaccine Formulated with a Novel TLR7-Dependent Adjuvant Rapidly Protects Mice through Antibodies, Effector CD4+ T Cells, and IL-17A.Staphylococcus aureus and Streptococcus pneumoniae interaction and response to pneumococcal vaccination: Myth or reality?Monoclonal Antibody Targeting Staphylococcus aureus Surface Protein A (SasA) Protect Against Staphylococcus aureus Sepsis and Peritonitis in Mice.MRSA Infections in HIV-Infected People Are Associated with Decreased MRSA-Specific Th1 Immunity.Rifampin Resistance rpoB Alleles or Multicopy Thioredoxin/Thioredoxin Reductase Suppresses the Lethality of Disruption of the Global Stress Regulator spx in Staphylococcus aureusCharacterization of a vraG Mutant in a Genetically Stable Staphylococcus aureus Small-Colony Variant and Preliminary Assessment for Use as a Live-Attenuated Vaccine against Intrammamary Infections.Synthesis and evaluation of a conjugate vaccine composed of Staphylococcus aureus poly-N-acetyl-glucosamine and clumping factor A.Octameric structure of Staphylococcus aureus enolase in complex with phosphoenolpyruvate.Protective efficacy of the chimeric Staphylococcus aureus vaccine candidate IC in sepsis and pneumonia modelsTargeting macrophage activation for the prevention and treatment of Staphylococcus aureus biofilm infections.Global antibody response to Staphylococcus aureus live-cell vaccinationStaphylococcus aureus Shifts toward Commensalism in Response to Corynebacterium Species.Successful selection of an infection-protective anti-Staphylococcus aureus monoclonal antibody and its protective activity in murine infection modelsStaphylococcal Enterotoxin B-specific monoclonal antibody 20B1 successfully treats diverse Staphylococcus aureus infections.Prevention and treatment of Staphylococcus aureus biofilms.Protein antigens increase the protective efficacy of a capsule-based vaccine against Staphylococcus aureus in a rat model of osteomyelitis.Omics Approaches for the Study of Adaptive Immunity to Staphylococcus aureus and the Selection of Vaccine Candidates.Innate Immune Memory Contributes to Host Defense against Recurrent Skin and Skin Structure Infections Caused by Methicillin-Resistant Staphylococcus aureus.Children with invasive Staphylococcus aureus disease exhibit a potently neutralizing antibody response to the cytotoxin LukAB.
P2860
Q26768436-78AB0BBA-67A8-4400-9A36-BDA43710B1C7Q26824837-0E7281B3-6586-4E42-8C39-F57616476B24Q26828726-0163CB07-F4AC-4EFC-89A9-045509570E34Q28539668-42CCAF27-B713-4721-BFE4-9AF7E05B9B20Q30416916-6CBF903E-CCEC-4F94-8BB6-6E6DF5CADFFBQ33714965-6BB8EC3D-16A7-4780-B977-4753491FD969Q33743499-C40FF180-E570-4EB4-A5D0-60DCE0653A4DQ33763029-37BF2458-9F54-456C-B0A3-08A74EB44078Q33788094-5BB65B93-FBAC-47F9-B4C4-09B1A8CCF487Q33812717-E34274B6-DAB0-4C62-BAB5-33AF3DA9FC04Q33995337-551FCFC7-FF6C-4D60-8F34-2C8109349FEAQ34250054-54EE63A5-F012-4005-B33C-9B76B5C641B9Q34315661-D89607A7-D489-456A-9733-3D01DCA2B8C8Q34450382-1C0803DB-4AF1-44B5-A62E-66B6F4D40BE9Q34522708-5A532623-0EB9-4839-A518-9B1954E3E5A1Q34792962-E1147258-AFC0-417A-B9DD-79F697143A54Q34889865-A518E63C-2D3F-4BC8-83D2-E6A6F708BAEFQ34983848-B08A06B3-A112-46B9-B121-1BD02CBEB03BQ34999275-7F2D5038-7A0B-42F0-864D-FBF1A183AD66Q35038206-5AB3DD25-280D-44E7-9E70-52E4ADD05079Q35229369-B861B703-2CFB-4EEA-A21F-22A4B548AAA5Q35904895-FE914C40-934D-4BA2-9E1C-68672FAC0DDBQ35932254-FA721031-A3B4-4160-B3D0-1870FA2637D3Q35939497-CE7ECD18-A7D1-4411-BC78-82584E2064DDQ35993709-8A350B81-776E-4E04-BDD1-A3D521D56B36Q36081351-276171C2-5D18-4ACF-834E-4DDEE2AEED5BQ36195087-1DE23DD8-4998-4F05-ABC6-AB4F766C46CCQ36213353-98D29D2E-64ED-4BD3-AD29-B015009D53F6Q36340351-3E6232EF-748F-40FD-AC22-26A58249C8EAQ36569841-D72EF944-3320-4BE2-8773-8F548EBB09E3Q36625631-4329765E-1082-4088-930A-3939161BCAD2Q36824281-97F2A8A0-E308-455B-AF7E-4796A404D6A3Q37182597-98574A00-1FE7-49CA-ABB3-BDE4ADCE15F3Q37269558-C2B5CB01-0000-4DC3-99B0-2B32F22A359EQ37332203-BEC36199-A2AF-4D82-8216-5607C611F4B1Q37482155-286E6F62-F01A-4034-A4ED-076B47EE8D05Q37548140-CEBC75DD-2694-4C37-91F4-5C91C18B76B7Q37566435-DE8712A5-26E7-416A-8F6B-C6F75C38E8A5Q37611964-4643207A-0CFB-441A-B9EB-38D6E3450BA1Q37643858-6B46831E-FAE3-41EA-88BB-20E317980A37
P2860
Challenges for a universal Staphylococcus aureus vaccine.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Challenges for a universal Staphylococcus aureus vaccine.
@en
Challenges for a universal Staphylococcus aureus vaccine.
@nl
type
label
Challenges for a universal Staphylococcus aureus vaccine.
@en
Challenges for a universal Staphylococcus aureus vaccine.
@nl
prefLabel
Challenges for a universal Staphylococcus aureus vaccine.
@en
Challenges for a universal Staphylococcus aureus vaccine.
@nl
P2860
P356
P1476
Challenges for a universal Staphylococcus aureus vaccine.
@en
P2093
Richard A Proctor
P2860
P304
P356
10.1093/CID/CIS033
P407
P577
2012-02-21T00:00:00Z